Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Royal Bank of Canada (RY) vs Zoetis Inc (ZTS) Price & Performance

Royal Bank of CanadaTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Royal Bank of Canada vs Zoetis Inc — how do they compare? Royal Bank of Canada trades at $206.91 (market cap $289.01B), while Zoetis Inc trades at $73.51 (market cap $30.40B). The key difference: Royal Bank of Canada is far larger — about 9.5× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.

RYZTS
Market Cap
$289.01B$30.40B
Sector
FinancialsHealth
52-Week High
$217.87$150.61
52-Week Low
$143.64$71.91
Dividend Yield
2.43%2.88%
Enterprise Value
$37.96B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Royal Bank of Canada

Royal Bank of Canada (RY) trades at $209.00, down 0.76% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $3.07 per share, beating estimates of $2.89, continuing a trend of quarterly beats. Revenue growth accelerated to $66.53 billion in 2025, with net income margin improving to 32.01% and ROE at 17.2%. Recent corporate actions include dividend declarations of $1.76 per share payable in November 2026.

RY demonstrates solid fundamental strength with consistent earnings outperformance and robust profitability metrics. The stock faces valuation concerns with a P/E of 18.23 and P/S of 5.69, while analyst sentiment remains mixed with 43% buy ratings versus 53% hold. Key risks include stretched bank valuations and macroeconomic sensitivity, but the company's diversified business model and record earnings provide stability for long-term investors.

Zoetis Inc

Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.

The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Royal Bank of Canada

Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.

Read more on RY

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS